15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a key enzyme in prostaglandin (PG) metabolism. This study provides important evidence for inhibition of hepatocellular carcinoma (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E 2 (15-keto-PGE 2 )/peroxisome proliferator-activated receptor-g (PPARg)/p21 WAF1/Cip1 signaling pathway. Forced overexpression of 15-PGDH inhibited HCC cell growth in vitro, whereas knockdown of 15-PGDH enhanced tumor growth parameters. In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of human HCC cells (Huh7) with overexpression of 15-PGDH led to significant inhibition of tumor growth, whereas knockdown of 15-PGDH enhanced tumor growth. In a separate tumor xenograft model in which mouse HCC cells (Hepa1-6) were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenovirus vector expressing 15-PGDH (pAd-15-PGDH) significantly inhibited xenograft tumor growth. The antitumor effect of 15-PGDH is mediated through its enzymatic product, 15-keto-PGE 2 , which serves as an endogenous PPARg ligand. Activation of PPARg by 15-PGDH-derived 15-keto-PGE 2 enhanced the association of PPARg with the p21 WAF1/Cip1 promoter and increased p21 expression and association with cyclin-dependent kinase 2 (CDK2), CDK4 and proliferating cell nuclear antigen. Depletion of p21 by short hairpin RNA reversed 15-PGDH-induced inhibition of HCC cell growth; overexpression of p21 prevented 15-PGDH knockdown-induced tumor cell growth. These results show a key 15-PGDH/15-keto-PGE 2 -mediated activation of PPARg and p21 WAF1/Cip1 signaling cascade that regulates hepatocarcinogenesis and tumor progression.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and its incidence is rising in the United States and around the world. [1] [2] [3] [4] The tumorigenic process is characterized by dysregulation of cell cycle progression and abnormal cell proliferation in the setting of chronic inflammation and fibrosis of the liver parenchyma. Consistent with the strong association between chronic inflammation and hepatocarcinogenesis, studies have shown that mediators of inflammation, such as prostaglandins (PGs), have an important role in hepatocarcinogenesis. [5] [6] [7] Previous studies have been focused on defining the role of cyclooxygenase-2 (COX-2, a key enzyme that mediates PG synthesis) in HCC. Indeed, the expression of COX-2 is increased in human and animal HCCs and in dysplastic hepatocytes. [5] [6] [7] In cultured HCC cells, forced overexpression of COX-2 increases tumor cell growth and invasiveness. Selective and non-selective COX-2 inhibitors prevent HCC cell growth in vitro and in animal models of hepatocarcinogenesis, [5] [6] [7] although these inhibitors are known to mediate effects through both COX-dependent and -independent mechanisms. These findings suggest the possibility of targeting COX-2 for prevention and treatment of HCC in patients. This approach is expected to be safe, given that selective COX-2 inhibitors do not adversely affect renal function in cirrhosis 8, 9 (in contrast to non-steroidal antiinflammatory drug (NSAID)-related renal failure in decompensated cirrhosis). However, on the other hand, in light of the increased cardiovascular side effect associated with some COX-2 inhibitors, [10] [11] [12] [13] it is imperative to identify specific molecular targets downstream of COX-2 for effective and safer anti-HCC therapy.
The amount of biologically active prostaglandin E 2 (PGE 2 ) is regulated by the balance of PGE 2 synthesis and degradation. The NAD þ -linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a member of the short-chain nonmetalloenzyme alcohol dehydrogenase protein family, which catalyzes oxidation of the 15(S)-hydroxyl group of PGE 2 , converting PGE 2 into 15-ketoprostaglandin E 2 (15-keto-PGE 2 ).
14 This enzymatic reaction causes inactivation of PGE 2 , a pro-inflammatory and pro-tumorigenic lipid mediator. Several recent studies suggest a tumor-suppressive role of 15-PGDH in several non-hepatic cancers. [15] [16] [17] [18] [19] [20] [21] [22] [23] However, to date, the action of 15-PGDH is largely attributable to its degradation of biologically active PGE 2 , with its 15-keto metabolite being considered largely inactive, and it remains unknown whether 15-PGDH is implicated in HCC.
This study was designed to examine the biological function and molecular mechanism of 15-PGDH in HCC by using complementary in vitro and in vivo approaches. We show herein that the antitumor effect of 15-PGDH is mediated through its enzymatic product, 15-keto-PGE 2 , which activates peroxisome proliferatoractivated receptor g (PPARg) leading to p21 WAF1/Cip1 expression and association with key downstream molecules including cyclindependent kinases (CDKs) and proliferating cell nuclear antigen (PCNA). Our data shift the current paradigm and disclose an important 15-PGDH/15-keto-PGE 2 -mediated activation of PPARg and p21 WAF1/Cip1 signaling axis that suppresses hepatocarcinogenesis and tumor progression.
RESULTS

15-PGDH inhibits HCC cell growth in vitro
To determine the role of 15-PGDH in HCC cell growth, we established human HCC cells with stable overexpression or knockdown of 15-PHDH. Human HCC cell line (Huh7) was stably transfected with the green fluorescent protein (GFP) control vector (pCMV6-AC-GFP), 15-PGDH expression vector (pCMV6-AV-GFP-15PGDH), RNA interference (RNAi) control vector (pGFP-V-RS) and 15-PGDH RNAi vector (pGFP-V-RS-15PGDH), respectively; successful overexpression or knockdown of 15-PGDH was confirmed by immunofluorescence and western blotting (Figure 1a ). Under immunofluorescence, the intensity of 15-PGDH staining was higher in 15-PGDH-overexpressed cells and decreased in 15-PGDH knockdown cells. Under western blotting analysis, the level of 15-PGDH protein was increased in Huh7 cells transfected with the 15-PGDH overexpression vector (56KD GFP-15PGDH fusion protein) and decreased in cells transfected with the 15-PGDH RNAi vector (29KD monomeric form, 58KD dimeric form). The aforementioned stable cell lines were cultured in vitro and their growth curves over time were measured by water soluble tetrazolium salt-1 (WST-1) assay. As shown in Figure 1b , overexpression of 15-PGDH inhibited cell growth, whereas RNAi knockdown of 15-PGDH enhanced it. Flow cytometry analysis showed that 15-PGDH overexpression increased the cells in G0/G1 phase (65.2 ± 10.2% versus 42.1 ± 9.7%, Po0.05) and decreased the cells in S phase (22.7±4.2% versus 47.3%±9.8, Po0.01; Figure 1c ). In contrast, 15-PGDH knockdown decreased the cells in G0/G1 phase (20.2% versus 45.2%, Po0.01) and increased the cells in S phase (69.4 ± 11.8% versus 45.1 ± 10.9%, Po0.05). The percentages of cells in G2 phase were not significantly altered when 15-PGDH was overexpressed or knocked down. Immunofluorescence for BrdU (a S phase marker) showed that the BrdU-positive cells were lower in 15-PGDH-overexpressed cells (6.71±1.52% compared with 39.41±8.13% in the corresponding control) and higher in 15-PGDH knockdown cells (81.84 ± 13.24% compared with 35.52 ± 5.78% in the corresponding control; Figure 1d ). Soft agar clonogenic assay showed that overexpression of 15-PGDH reduced clonogenic growth, whereas knockdown of 15-PGDH enhanced it. The colony formation rates for the two mock Huh7 cells lines were 23.4 ± 4.5% and 24.5 ± 6.2%, respectively, whereas the colony formation rate was 5.67±1.59% for 15-PGDHoverexpressed cells and 61.4±11.87% for 15-PGDH knockdown cells (Figure 1e ). Taken together, these findings demonstrate that 15-PGDH signaling induces HCC cell cycle arrest at G1/S transit and inhibits cell proliferation, DNA synthesis and clonogenic growth.
15-PGDH inhibits HCC growth in severe combined immunodeficiency (SCID) mice To examine the effect of 15-PGDH signaling on HCC growth in vivo, the above four stable Huh7 cell lines were inoculated into SCID mice and the animals were closely monitored for tumor development. As shown in Figure 2a, Figure 2b ). Accordingly, western blotting confirmed that the level of PCNA was lower in 15-PGDH-overexpressed tumors and higher in 15-PGDH knockdown tumors (Figure 2c ). Furthermore, 15-PGDH overexpression increased the expression level of the cyclin kinase inhibitor p21 WAF1/Cip1 in xenograft tumors, whereas 15-PGDH knockdown reduced it (Figure 2c ).
15-PGDH inhibits HCC growth in C57BL/6 mice We next utilized a complementary syngeneic HCC xenograft model in which a murine HCC cell line originated from C57BL/6 mouse strain (Hepa1-6) was inoculated subcutaneously at armpit in C57BL/6J mice. When the tumors become palpable, an adenoviral vector expressing 15-PGDH (pAd-15-PGDH) or the pAd control vector was directly injected into the tumor modules (at 3-day interval, starting 10 days after inoculation till the end of the experiment). The tumor size in the pAd-15-PGDH-injected group was significantly smaller compared with the pAd-control group (Po0.01; Figure 3a) . The average tumor weight in pAd-15-PGDH-treated group was also significantly lower compared with the pAd control group (0.57 ± 0.12 versus 2.51 ± 0.58 g, Po0.01; Figure 3b ). Increased 15-PGDH protein in pAd-15PGDH-treated tumors was confirmed by western blotting analysis (Figure 3c ). pAd-15PGDH treatment decreased PCNA expression in xenograft tumor cells (Figures 3d and e) Figure 4C ). These observations are in accordance with the enzymatic action of 15-PGDH (converting PGE 2 to 15-keto-PGE 2 ). 
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Consistent with activation of PPARg by 15-keto-PGE 2 in 3T3-L1 fibroblasts, 24 we observed that 15-PGDH overexpression in HCC cells increased PPARg binding to PPAR response element (PPRE), whereas 15-PGDH knockdown reduced the PPARg binding to PPRE, as determined by electrophoretic mobility shift assay ( Figure 4D ) and by DNA pull-down assay ( Figure 4E ). The involvement of 15-keto-PGE 2 in 15-PGDH-induced PPARg-PPRE binding in HCC cells was supported by the observation that the effect was blocked by overexpression of 15-oxoprostaglandin-D 13 -reductase 2 (PGR2), which catalyzes the reaction converting 15-keto-PGE 2 to 13,14-dihydro-15-keto-PGE 2 . Consistent with these findings, we found that 15-PGDH overexpression increased PPRE luciferase reporter activity, whereas 15-PGDH knockdown reduced it ( Figure 4F ). The effect of 15-PGDH on PPRE reporter activity was abolished when PGR2 was overexpressed or when the cells were treated with 10 mM GW9662, a PPARg antagonist. Furthermore, treatment of wild-type Huh7 cells with 15-keto-PGE 2 increased the PPRE reporter activity and the effect was abolished by PGR2 overexpression or by GW9662 treatment (10 mM). Taken together, these results show that 15-PGDH-derived 15-keto-PGE 2 is able to activate PPARg in HCC cells.
15-PGDH-derived 15-keto-PGE 2 induces p21
WAF1/Cip1 gene transcription through PPARg Given that 15-PGDH signaling increased p21 WAF1/Cip1 expression (see Figures 2, 3 and 5) and that PPARg is a ligand-dependent transcription factor that regulates target gene expression through binding to PPRE, we postulated that PPARg might be a key transcription factor that mediates 15-PGDH/15-keto-PGE 2 -induced p21 WAF1/Cip1 expression in HCC cells. Indeed, sequence alignment analysis revealed the presence of PPRE consensus sequence (C(A/G)(A/G)A(A/T)CT) within the p21 WAF1/Cip1 promoter ( À 2151 to À 2145, À 1782 to À 1188, À 1186 to À 1179, À 1000 to À 993). Consequently, we utilized a luciferase reporter construct driven by the p21 gene promoter (from -2192 to þ 10, containing the PPRE consensus sequences) to evaluate the impact of 15-PGDH/15-keto-PGE 2 on p21 promoter activity. As shown in #6  #5  #4  #3  #2  #1  6 C  5  4  3  2  1   #6  #5  #4  #3  #2  #1   #6  #5  #4  #3  #2  #1  #6  #5  #4  #3 #2 #1 Figure 3 . The effect of 15-PGDH on HCC growth in syngeneic C57BL/6J mice. Hepa1-6 cells (1 Â 10 8 cells in 0.2 ml of phosphate-buffered saline (PBS)) were inoculated subcutaneously at armpit in C57BL/6J mice. When the tumor nodules become palpable, the pAd control virus or pAd-15-PGDH (10 10 plaque-forming unit) was injected directly to the tumor nodules (the injection was performed every 3 days, from the 10th day to the 28th day). After the last injection, the mice were observed for additional 3 days before killing to recover tumor nodules. The wet weight of each tumor was recorded. The tumor diameters were measured by a caliper in two dimensions. The tumor volume was calculated by using the formula V ¼ L/2 Â w 15-PGDH inhibits HCC via 15-keto-PGE 2 /PPARg/p21 D Lu et al Figure 5A , 15-PGDH overexpression increased p21 promoter luciferase reporter activity, whereas 15-PGDH knockdown reduced it; this effect was reversed by overexpression of PGR2 or by treatment with the PPARg antagonist GW9662 (10 mM). Accordingly, treatment of the wild-type Huh7 cells with 15-keto-PGE 2 (10 mM) significantly enhanced the p21 promoter reporter activity and this effect was abolished by PGR2 overexpression or GW9662 treatment (10 mM). These findings suggest the involvement of PPARg in 15-PGDH/15-keto-PGE 2 -induced p21 gene transcription. Consistent with these results, chromatin immunoprecipitation (IP) assay showed that 15-PGDH overexpression enhanced the binding of PPARg to p21 promoter DNA, whereas 15-PGDH knockdown reduced this interaction ( Figures 5B and C) . Overexpression of PGR2 reversed 15-PGDH-mediated interaction between PPARg and p21 promoter DNA. Treatment of wild-type Huh7 cells with 15-keto-PGE 2 (10 mM) also enhanced PPARg association with the p21 promoter DNA and the effect was blocked by the PPARg antagonist GW9662 (10 mM). Treatment of wild-type Huh7 cells with the pharmacologic PPARg agonist, ciglitazone, also increased PPARg association with the p21 promoter ( Figure 5D ). These observations demonstrate that 15-PGDH-derived 15-keto-PGE 2 induces PPARg association with the p21 promoter and enhances p21 transcription in HCC cells. This assertion is further supported by the western blot analyses showing that the p21 protein and phosphorylated p21 were increased in 15-PGDH-overexpressed cells but decreased in 15-PGDH knockdown cells ( Figure 5E ). The 15-PGDH-induced increase in p21 protein and phosphorylated p21 was also influenced by PGR2 and PPARg (attenuated by PGR2 overexpression or by PPARg knockdown; enhanced by PPARg overexpression). Taken together, these results establish an important role of PPARg in 15-PGDH/15-keto-PGE 2 -induced p21 expression in HCC cells.
The effect of 15-PGDH on p21 WAF1/Cip1 association with PCNA and CDKs in HCC cells Consistent with the notion that p21 inhibits PCNA and CDKs in the nucleus, western blotting analysis showed that 15-PGDH overexpression caused accumulation of p21 in the nucleus and decrease of p21 in the cytoplasm (Figure 6a ). In contrast, 15-PGDH knockdown led to reduction of p21 in the nucleus and increase of p21 in the cytoplasm. Co-IP analysis showed that 15-PGDH overexpression increased the interaction between p21 and PCNA, whereas 15-PGDH knockdown inhibited their interaction (Figure 6b ). In parallel, 15-PGDH overexpression also increased p21 interaction with CDK2, CyclinE, CDK4 and CyclinD1, whereas 15-PGDH knockdown inhibited these interactions (Figures 6c  and d) . Furthermore, 15-PGDH overexpression enhanced E2F1 binding to RB and decreased E2F1 binding to C-myc, whereas an opposite pattern of interactions was observed in cells with 15-PGDH knockdown (Figure 6e ). These findings demonstrate that 15-PGDH signaling influences p21 interaction with key cell cycleregulatory molecules. 
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Regulation of p21 WAF1/Cip1 by 15-PGDH is independent of p53 in HCC cells Given that the expression of p21 in human cells is regulated by wild-type p53, we performed further experiments to determine whether p53 is implicated in 15-PGDH-mediated regulation of p21 in HCC cells. To this end, we utilized HepG2 cell line that expresses wild-type p53 (Huh7 cells have p53 mutation). Western blotting analysis showed that short hairpin RNA depletion of p53 did not alter 15-PGDH-induced p21 expression (nuclear accumulation and cytoplasmic reduction), despite that p53 depletion reduced p21 protein in cells without 15-PGDH overexpression (Figure 7a) . Similarly, luciferase reporter activity assay showed that short hairpin RNA depletion of p53 did not alter 15-PGDH-induced p21 promoter activity, although p53 depletion reduced p21 promoter reporter activity in cells without 15-PGDH overexpression (Figure 7b) . Furthermore, p53 depletion did not influence 15-PGDH-induced interaction of p21 with CDK2, CDK4, PCNA and the interaction between E2F1 and RB, although p53 depletion decreased the interactions of these molecules in cells without 15-PGDH overexpression (Figure 7c ). Finally, chromatin IP assay showed that p53 depletion did not alter 15-PGDH-induced PPARg binding to the p21 promoter DNA, although p53 depletion reduced their binding in cells without 15-PGDH overexpression (Figure 7d ). These results suggest that 15-PGDH signaling upregulates p21 expression in HCC cells through mechanisms independent of p53.
p21
WAF1/Cip1 mediates the antitumor effect of 15-PGDH To further evaluate the role of p21 in 15-PGDH-mediated antitumor effect, additional experiments were performed to determine whether overexpression or knockdown of p21 would influence 15-PGDH-regulated cell growth. As shown in Figure 8A , knockdown of p21 reversed 15-PGDH-induced inhibition of HCC cell proliferation and clonogeneic growth. On the other hand, overexpression of p21 prevented cell proliferation and clonogenic growth induced by 15-PGDH knockdown ( Figure 8B ). These results show a key role of p21 in 15-PGDH-mediated inhibition of HCC cell growth.
DISCUSSION
Recent studies suggest an emerging role of 15-PGDH in several non-hepatic cancers. [15] [16] [17] [18] [19] [20] [21] [22] [23] [25] [26] [27] [28] [29] Reduction of 15-PGDH is associated with enhanced cell proliferation and is an independent predictor for poor survival in gastric adenocarcinoma. 27 A haplotype in the 15-PGDH gene is positively associated with colorectal cancer risk. 20 In mouse models of colonic carcinogenesis, overexpression of 15-PGDH decreases cancer cell growth or delays tumor formation, whereas deletion of 15-PGDH increases susceptibility to chemically or genetically induced colon tumors. 16 Targeted adenovirus-mediated delivery of 15-PGDH gene inhibited colon cancer growth in a mouse xenograft model. 30 The hepatocyte growth factor and its receptor c-Met signaling promotes PGE 2 biogenesis in colorectal cancer cells via upregulation of COX-2 and downregulation of 15-PGDH. 31 Reciprocal regulation between COX-2 and 15-PGDH expression has been documented in several cancers. 32 Omega-3 polyunsaturated fatty acids reduce the level of PGE 2 in HCC and cholangiocarcinoma cells through downregulation of COX-2 and induction of 15-PGDH. 33, 34 Anticancer therapeutics, such as transforming growth factor-b1, glucocorticoids and histone deacetylase inhibitors, have been shown to exert their anti-carcinogenic activity in part through induction of 15-PGDH expression. 26, 35 All of these findings suggest 15-PGDH inhibits HCC via 15-keto-PGE 2 /PPARg/p21 D Lu et al a tumor-suppressive function of 15-PGDH. However, to date, the action of 15-PGDH is largely attributable to its degradation of biologically active PGE 2 , with its 15-keto metabolite being considered largely inactive. This study provides paradigmshifting evidence for an active role of 15-keto-PGE 2 in 15-PGDHmediated inhibition of cancer cell growth. Our results reveal that 15-PGDH-derived 15-keto-PGE 2 is a natural PPARg ligand, which induces PPARg association with p21 WAF1/Cip1 promoter and enhances p21 gene expression leading to inhibition of HCC growth (illustrated in Figure 9 ). p21 WAF1/Cip1 is a potent inhibitor of CDKs. It inhibits cell cycle progression through binding to cyclin-cdk complexes. [36] [37] [38] Association of p21 to cyclin-cdk complexes also prevents phosphorylation of the retinoblastoma protein thus preventing the release of E2F transcription factor. 39 In addition, p21 also binds to PCNA and interferes with PCNA-dependent DNA polymerase activity leading to inhibition of DNA replication. 40 The growth inhibitory action of p21 is attributed to the functions of the carboxy-terminal PCNA-binding domain as well as the aminoterminal CDK-cyclin inhibitory domain. 41, 42 Consistent with the growth inhibitory effect of p21, we have shown that 15-PGDHderived 15-keto-PGE 2 induces p21 expression in HCC cells and this signaling pathway suppresses HCC cell growth. The role of p21 in 15-PGDH/15-keto-PGE 2 -mediated inhibition of HCC cell growth is attested by the observations that p21 knockdown reversed 15-PGDH-induced inhibition of tumor cell growth and that overexpression of p21 prevented the cell growth induced by 15-PGDH knockdown.
PPARg is a ligand-activated nuclear transcription factor regulating the expression of target genes by binding to PPRE in target genes. 43, 44 The activity of PPARg is regulated by several ligands, including thiazolidinediones (such as ciglitazone), 15-deoxy-D increased PPARg binding to PPRE as determined by electrophoretic mobility shift assay and DNA pull-down assays; (2) 15-PGDH knockdown reduced PPARg binding to PPRE as determined by electrophoretic mobility shift assay and DNA pulldown assays; (3) the effect of 15-PGDH on PPARg-PPRE binding was blocked by overexpression of PGR2, an enzyme that converts 15-keto PGE 2 to 13,14-dihydro-15-keto PGE 2 ; (4) 15-PGDH overexpression increased PPRE luciferase reporter activity; (5) 15-PGDH knockdown reduced PPRE reporter activity; (6) the effect of 15-PGDH on PPRE reporter activity was abolished by overexpression of PGR2 or by treatment with the PPARg antagonist GW9662; (7) 15-keto-PGE 2 increased PPRE reporter activity and the effect was abolished by PGR2 overexpression or by GW9662 treatment.
Another important finding in this study is that 15-PGDH-derived 15-keto-PGE 2 increases PPARg association with p21 gene promoter thus enhancing p21 gene transcription. Evidences supporting the role of PPARg in 15-PGDH/15-keto-PGE 2 -induced p21 gene transcription include: (1) 15-PGDH overexpression increased PPARg association with p21 promoter DNA and enhanced p21 luciferase reporter activity; (2) 15-PGDH knockdown decreased PPARg association with p21 promoter DNA and reduced p21 luciferase reporter activity; (3) the effect of 15-PGDH on p21 promoter reporter activity and PPARg binding was reversed by overexpression of PGR2 or by treatment with the PPARg antagonist GW9662; (4) 15-keto-PGE 2 treatment increased p21 promoter reporter activity/PPARg association and the effect was blocked by PGR2 overexpression or by GW9662 treatment; (5) 15-PGDH overexpression increased p21 protein whereas 15-PGDH knockdown decreased p21 protein; (6) the effect of 15-PGDH on p21 protein induction was influenced by PGR2 and PPARg.
The results of this study depict a key 15-PGDH/15-keto-PGE 2 / PPARg/p21 signaling axis that suppresses hepatocarcinogenesis and tumor progression. As 15-PGDH converts oncogenic PGE 2 to tumor-suppressive 15-keto-PGE 2 , induction of endogenous 15-PGDH expression or delivery of exogenous 15-PGDH/15-keto-PGE 2 may represent promising future therapeutic interventions. It is conceivable that this approach may provide more effective antitumor therapy with fewer side effects compared with the selective COX-2 inhibitors.
MATERIALS AND METHODS
Cell lines
Human HCC cell lines (Huh7 and HepG2) and murine HCC cell line (Hepa1-6) were obtained from ATCC (Manassas, VA, USA). The cells were maintained in minimum essential medium (Gibco BRL Life Technologies, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated (56 1C, 30 min) fetal bovine serum (Sigma, St Louis, MO, USA) in a humidified atmosphere of 5% CO 2 incubator at 37 1C.
Selection of Huh stable cell lines
Huh7 cells were transfected with pCMV6-AC-GFP, pCMV6-AV-GFP-15PGDH, pGFP-V-RS, pGFP-V-RS-15PGDH using the transfection reagent Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) (the plasmid constructs were obtained from Origene, Rockville, MD, USA). Forty-eight hours after transfection, the cells were cultured with the selection media containing 1-2 mg/ml G418 (Calbiochem, San Diego, CA, USA) for 15-PGDH overexpression or 1-2 mg/ml Puromycin (Invitrogen) for 15-PGDH knockdown. The selection media were replaced every 3 days. Distinct colony of the surviving cells was transferred onto 96-well plate and the cells were continuously maintained in the selection media. The transfection efficiency was verified by immunofluorescence staining with anti-GFP antibody To select cells with 15-PGDH overexpression plus p21 depletion, Huh7 cells stably transfected with the 15-PGDH expression vector (pCMV6-GFP-AC-15PGDH) were subsequently transfected with the p21 RNAi vector (pGFP-V-RS-WAF1/Cip1/p21, obtained from Origene). The double transfection cells were selected by using G418 and Puromycin.
To select cells with 15-PGDH knockdown plus p21 overexpression, the Huh7 cells stably transfected with the 15-PGDH RNAi vector (pGFP-V-RS-15PGDH) were subsequently transfected with the p21 expression vector (pcDNA3/WAF1/Cip1/p21, obtained from Addgene, Cambridge, MA, USA). The double transfection cells were selected by using Puromycin and G418.
Cell proliferation WST-1 assay
The cells were synchronized in G0 phase by serum deprivation and then released from growth arrest by re-exposure to complete medium with serum. Cell proliferation was detected by reagent WST-1 kit (Roche, Indianapolis, IN, USA) according to the manufacturer instruction. Cell growth curve was based on the normalized values of OD450 and each point represents the mean of three independent samples.
Cell cycle analysis
Cell cycle distribution was determined by using flow cytometry. In all, 5 Â 10 6 cells in a 10 cm dish were grown overnight. Then the cells were then kept in serum-deprived medium for 48 h for synchronization to G0 phase. The cells were released from growth arrest by re-exposure to 10% fetal bovine serum for 24 h. Cells were collected by trypsinization followed by centrifugation, washed once with phosphate-buffered saline, and resuspended in 0.2 ml of ice-cold phosphate-buffered saline. The collected cells were fixed in 70% cold ethanol (in 50 mM glycine buffer (pH 2.0)) overnight at À 20 1C. In total, 100 mg/ml RNase A (Qiagen, Valencia, CA, USA) was added to the cells with incubation for 30 min at 37 1C. The cells were resuspended in 0.5 ml 100 mg/ml propidium iodide solution Boehoringer Nannheim Co. (Indianapolis, IN, USA DNA pull-down Cells were lysed by sonication in HKMG buffer (10 mM HEPES, PH7.9, 100 mM KCl, 5 mM MgCl 2 , 100% glycerol, 1 mM DTT and 0.5% NP40) containing protease and phosphatase inhibitors for the preparation of nuclear exact. The nuclear extracts were precleared with Streptavidinagarose Resin (Thermo, Pittsburgh, PA, USA) for 1 h and then incubated with 1 mg of biotinylated double-stranded oligonucleotides (corresponding to the PPRE consensus site in the p21 promoter): P1: 5 0 -Biotin-AGGTCACTGGTCA-3 0 ; P2: 5 0 -TGACCAGTGACC-3 0 (synthesized by Integrated DNA Technologies, Coralville, IA, USA), along with 10 mg of poly(dI-dC) (Sigma) for 24 h. DNA-bound proteins were collected with streptavidinagarose resin and the samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting analysis.
Luciferase reporter assay Cells (1 Â 10 5 per well in six-well plate) were transiently transfected with 1 mg of luciferase construct (pGL3-PPRE or pGL3-WAF1/Cip1/p21 promoter) and 0.1 mg of pRL-Tk (Addgene) using Lipofectiamine 2000 (Invitrogen; with additionally plasmids as indicated). At 36 h after transfection, the cells were harvested with lysis buffer and luciferase activities of the cell extracts were measured using the dual luciferase assay system (Promega, Madison, WI, USA). The luciferase activity was normalized for transfection efficiency with Renilla luciferase activity.
Xenograft tumor study in SCID mice
Four-week-male athymic NOD CB17-prkdc/SCID mice were purchased from Jackson Labratory (Bar Harbor, ME, USA) and maintained in the animal facilities according to the protocol approved by the American Association for Accreditation of Laboratory Animal Care. Six athymic SCID mice per group were injected subcutaneously at the armpit area with Huh7 cells stably transfected with pCMV6-AC-GFP, pCMV6-AV-GFP-15PGDH, pGFP-V-RS, pGFP-V-RS-15PGDH, respectively (1 Â 10 8 cells in 100 ml of phosphatebuffered saline). The mice were observed over 4 weeks and then killed to recover the tumors. The wet weight of each tumor was determined. Portion of the tissue from each tumor was snap frozen. Additional portion 
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of each tumor was fixed in 4% paraformaldehyde and embedded in paraffin for hematoxylin and eosin stain and for PCNA immunostain.
Xenograft tumor study in C57BL/6J mice Mouse HCC cell line (Hepa1-6) (1 Â 10 8 cells in 0.2 ml of phosphatebuffered saline) was inoculated subcutaneously at armpit into syngenetic C57BL/6J mice. The mice were divided into two groups and subjected to intratumoral injection of pAd or pAd-15-PGDH (10 10 plaque-forming unit). The diameters of the tumors were measured every 3 days and the tumor volume was calculated using the formula V ¼ L/2 Â w 2 . The mice were killed 31 days after inoculation to recover the tumor tissue. The wet weight of each tumor was determined for each mouse. A portion of the tissue from each tumor was snap frozen. Additional portion of each tumor was fixed in 4% paraformaldehyde and embedded in paraffin for hematoxylin and eosin stain and for PCNA immunostain.
Statistical analysis
The values are presented as mean±s.e.m. unless otherwise noted, with a minimum of three replicates. The results were evaluated by SPSS 12.0 statistical software from SPSS Inc (Chicago, IL, USA) and student's t-test was used for comparisons, with Po0.05 considered significant. ABBREVIATIONS 15-PGDH, 15-hydroxyprostaglandin dehydrogenase; 15-keto-PGE 2 , 15-keto-prostaglandin E 2 ; CDK, cyclin-dependent kinase; COX-2, cyclooxygenase-2; HCC, hepatocellular carcinoma; IP, immunoprecipitation; PCNA, proliferating cell nuclear antigen; PGE 2 , prostaglandin E 2 ; PGR, 15-oxoprostaglandin-D 13 -reductase; PPARg, peroxisome proliferator-activated receptor-g; PPRE, peroxisome proliferator response element; SCID, severe combined immunodeficiency
